December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Bristol Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
News headline image
Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Reports Second Quarter Financial Results for 2026
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global Operations
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Launches “Won't Lose” Media Campaign Ahead of FIFA World Cup 2026™
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Reports First Quarter Financial Results for 2026
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program Marks Ten Years
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.